Figure 1.
64Cu-daratumumab biodistribution in subjects imaged without preinfusion of unlabeled daratumumab. (A) Maximum intensity projections showing diffuse 64Cu-daratumumab uptake in the liver, spleen, spine, and pelvis among the 3 patients. Magnification of the cervical (B) and pelvic (C) regions showing reduced radiotracer uptake (red squares) in regions corresponding to the sites in which patient 1 and patient 3 received palliative radiation. pts, patients.

64Cu-daratumumab biodistribution in subjects imaged without preinfusion of unlabeled daratumumab. (A) Maximum intensity projections showing diffuse 64Cu-daratumumab uptake in the liver, spleen, spine, and pelvis among the 3 patients. Magnification of the cervical (B) and pelvic (C) regions showing reduced radiotracer uptake (red squares) in regions corresponding to the sites in which patient 1 and patient 3 received palliative radiation. pts, patients.

Close Modal

or Create an Account

Close Modal
Close Modal